Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Maria T. Polianova"'
Autor:
Travis Quigley, Maria T Polianova, Noopur Raje, David W LeFleur, Scott Currence, Michael R. Bishop, Daniella Cook, Marcela V. Maus, Carissa Mangus, Maria Sabatino, Justin P Edwards, Allegra Mondillo, Janine M Buonato, Matthew J. Frigault, Angela Shen, Heather Daley, Elizabeth O'Donnell, Laura Richman
Publikováno v:
Blood. 136:2-2
Introduction: Chimeric Antigen Receptor (CAR) T cell therapies directed against B-cell maturation antigen (BCMA) have demonstrated compelling clinical activity and manageable safety in subjects with relapsed and refractory Multiple Myeloma (RRMM). Th
Autor:
Dominique Schols, Stefano Aquaro, Michael R. Ruff, Carlo Federico Perno, Maria T. Polianova, Candace B. Pert, Michela Pollicita, Alessandro Ranazzi
Publikováno v:
Antiviral Chemistry and Chemotherapy. 18:285-295
Monocytes/macrophages (M/M) are strategic reservoirs of HIV-1, spreading the virus to other cells and inducing apoptosis in T-lymphocytes, astrocytes and neurons. M/M are commonly infected by R5 HIV-1 strains, which use the chemokine receptor CCR5. D
Autor:
Gifford Leoung, Michael R. Ruff, Candace B. Pert, Quan-en Yang, Francis W. Ruscetti, Maria T. Polianova
Publikováno v:
Current HIV Research. 1:51-67
Peptide T, named for its high threonine content (ASTTTNYT), was derived by a database search which assumed that a relevant receptor binding epitope within env (gp120) would have sequence homology to a known signaling peptide. Binding of radiolabeled
Publikováno v:
Antiviral research. 67(2)
The chemokine receptor CCR5 plays a crucial role in transmission of HIV isolates, which predominate in the early and middle stages of infection, as well as those, which populate the brain and cause neuro-AIDS. CCR5 is therefore an attractive therapeu
Autor:
Rochelle E. Tractenberg, Scott Strang, Maria T. Polianova, Candace B. Pert, Gifford Leoung, Francis W. Ruscetti, Michael R. Ruff
Publikováno v:
Peptides. 24(7)
D-Ala-Peptide T-amide (DAPTA), the first viral entry inhibitor, blocks chemokine (CCR5) receptors, not CD4. Early investigators could not "replicate" DAPTAs potent in vitro antiviral effect using the lab-adapted, X4, peptide T-insensitive strain, III